{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:13:50Z","timestamp":1753888430728},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2010,6,25]],"date-time":"2010-06-25T00:00:00Z","timestamp":1277424000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1007\/s00115-010-2999-3","type":"journal-article","created":{"date-parts":[[2010,6,23]],"date-time":"2010-06-23T13:12:11Z","timestamp":1277298731000},"page":"796-806","source":"Crossref","is-referenced-by-count":9,"title":["S3-Leitlinie \u201eDemenzen\u201c"],"prefix":"10.1007","volume":"81","author":[{"given":"L.","family":"Fr\u00f6lich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,6,25]]},"reference":[{"key":"2999_CR1","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1001\/jama.289.21.2819","volume":"289","author":"Aisen","year":"2003","unstructured":"Aisen PS, Schafer KA, Grundman M et al (2003) Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 289(21):2819\u20132826","journal-title":"JAMA"},{"key":"2999_CR2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1468-1331.2006.01222.x","volume":"13","author":"Alvarez","year":"2006","unstructured":"Alvarez XA, Cacabelos R, Laredo M et al (2006) A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer\u2019s disease. Eur J Neurol 13(1):43\u201354","journal-title":"Eur J Neurol"},{"key":"2999_CR3","unstructured":"AWMF (2009) S3-Leitlinie IS. Hormontherapie in der Peri- und Postmenopause (HT). AWMF 015\/062"},{"key":"2999_CR4","first-page":"CD000442","volume":"Rev","author":"Birks","year":"2003","unstructured":"Birks J, Flicker L (2003) Selegiline for Alzheimer\u2019s disease. Cochrane Database Syst Rev (1):CD000442","journal-title":"Cochrane Database Syst"},{"key":"2999_CR5","first-page":"CD003120","volume":"Rev","author":"Birks","year":"2002","unstructured":"Birks J, Grimley EV, Van Dongen M (2002) Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev (4):CD003120","journal-title":"Cochrane Database Syst"},{"key":"2999_CR6","first-page":"CD003120","volume":"Rev","author":"Birks","year":"2009","unstructured":"Birks J, Grimley Evans J (2009) Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev (1):CD003120","journal-title":"Cochrane Database Syst"},{"key":"2999_CR7","first-page":"CD005593","volume":"Rev","author":"Birks","year":"2006","unstructured":"Birks J (2006) Cholinesterase inhibitors for Alzheimer\u2019s disease. Cochrane Database Syst Rev (1):CD005593","journal-title":"Cochrane Database Syst"},{"key":"2999_CR8","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1212\/01.wnl.0000266627.96040.5a","volume":"69","author":"Black","year":"2007","unstructured":"Black SE, Doody R, Li H et al (2007) Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 69(5):459\u2013469","journal-title":"Neurology"},{"key":"2999_CR9","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1345\/aph.1E495","volume":"39","author":"Boothby","year":"2005","unstructured":"Boothby LA, Doering PL (2005) Vitamin C and vitamin E for Alzheimer\u2019s disease. Ann Pharmacother 39(12):2073\u20132080","journal-title":"Ann Pharmacother"},{"key":"2999_CR10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1474-4422(08)70261-8","volume":"8","author":"Burns","year":"2009","unstructured":"Burns A, Bernabei R, Bullock R et al (2009) Safety and efficacy of galantamine (Reminyl) in severe Alzheimer\u2019s disease (the SERAD study): A randomised, placebo-controlled, double-blind trial. Lancet Neurol 8(1):39\u201347","journal-title":"Lancet Neurol"},{"key":"2999_CR11","unstructured":"CHMP (2008) Guideline on medicinal products for the treatment of Alzheimer\u2019s Disease and other dementias. European Medicines Agency, London. Doc. Ref. CPMP\/EWP\/553\/95 Rev. 1"},{"key":"2999_CR12","unstructured":"Cohen J (ed) (1998) Statistical power analysis for the behavioral sciences. (2nd edn.). Erlbaum, Hillsdale NJ"},{"key":"2999_CR13","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s00213-003-1686-5","volume":"172","author":"Deakin","year":"2004","unstructured":"Deakin JB, Rahman S, Nestor PJ et al (2004) Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology 172(4):400\u2013408","journal-title":"Psychopharmacology"},{"key":"2999_CR14","doi-asserted-by":"crossref","unstructured":"Diener H-C, Putzki N (Hrsg) (2008) Prim\u00e4r- und Sekund\u00e4rpr\u00e4vention der zerebralen Isch\u00e4mie. Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. 4. \u00fcberarb Aufl. Thieme, Stuttgart","DOI":"10.1055\/b-0034-18820"},{"key":"2999_CR15","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa041470","volume":"351","author":"Emre","year":"2004","unstructured":"Emre M, Aarsland D, Albanese A et al (2004) Rivastigmine for dementia associated with Parkinson\u2019s disease. N Engl J Med 351(24):2509\u20132518","journal-title":"N Engl J Med"},{"key":"2999_CR16","first-page":"64","volume":"127","author":"Emre","year":"2002","unstructured":"Emre M (2002) Switching cholinesterase inhibitors in patients with Alzheimer\u2019s disease. Int J Clin Pract 127 (Suppl):64\u201372","journal-title":"Int J Clin Pract"},{"key":"2999_CR17","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0140-6736(02)08267-3","volume":"359","author":"Erkinjuntti","year":"2002","unstructured":"Erkinjuntti T, Kurz A, Gauthier S et al (2002) Efficacy of galantamine in probable vascular dementia and Alzheimer\u2019s disease combined with cerebrovascular disease: a randomised trial. Lancet 359(9314):1283\u20131290","journal-title":"Lancet"},{"key":"2999_CR18","first-page":"CD004143","volume":"Rev","author":"Farquhar","year":"2009","unstructured":"Farquhar C, Marjoribanks J, Lethaby A et al (2009) Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev (2):CD004143","journal-title":"Cochrane Database Syst"},{"key":"2999_CR19","first-page":"CD003159","volume":"Rev","author":"Fioravanti","year":"2001","unstructured":"Fioravanti M, Flicker L (2001) Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment. Cochrane Database Syst Rev (4):CD003159","journal-title":"Cochrane Database Syst"},{"key":"2999_CR20","first-page":"CD001011","volume":"Rev","author":"Flicker","year":"2001","unstructured":"Flicker L, Grimley Evans G (2001) Piracetam for dementia or cognitive impairment. Cochrane Database Syst Rev (2):CD001011","journal-title":"Cochrane Database Syst"},{"key":"2999_CR21","first-page":"CD002229","volume":"Rev","author":"Gabriel","year":"2005","unstructured":"Gabriel SR, Carmona L, Roque M et al (2005) Hormone replacement therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev (2):CD002229","journal-title":"Cochrane Database Syst"},{"key":"2999_CR22","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1185\/030079903125002450","volume":"19","author":"Gauthier","year":"2003","unstructured":"Gauthier S, Emre M, Farlow MR et al (2003) Strategies for continued successful treatment of Alzheimer\u2019s disease: switching cholinesterase inhibitors. Curr Med Res Opin 19(8):707\u2013714","journal-title":"Curr Med Res Opin"},{"key":"2999_CR23","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/archinternmed.2009.43","volume":"169","author":"Gill","year":"2009","unstructured":"Gill SS, Anderson GM, Fischer HD et al (2009) Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Intern Med 169(9):867\u2013873","journal-title":"Arch Intern Med"},{"key":"2999_CR24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000106595","volume":"8","author":"Herrmann","year":"1997","unstructured":"Herrmann WM, Stephan K, Gaede K, Apeceche M (1997) A multicenter randomized double-blind study on the efficacy and safety of nicergoline in patients with multi-infarct dementia. Dement Geriatr Cogn Disord 8(1):9\u201317","journal-title":"Dement Geriatr Cogn Disord"},{"key":"2999_CR25","first-page":"CD001015","volume":"Rev","author":"Higgins","year":"2003","unstructured":"Higgins JP, Flicker L (2003) Lecithin for dementia and cognitive impairment. Cochrane Database Syst Rev (3):CD001015","journal-title":"Cochrane Database Syst"},{"key":"2999_CR26","first-page":"CD003799","volume":"Rev","author":"Hogervorst","year":"2002","unstructured":"Hogervorst E, Yaffe K, Richards M, Huppert F (2002) Hormone replacement therapy to maintain cognitive function in women with dementia. Cochrane Database Syst Rev (3):CD003799","journal-title":"Cochrane Database Syst"},{"key":"2999_CR27","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1159\/000122961","volume":"25","author":"Homma","year":"2008","unstructured":"Homma A, Imai Y, Tago H et al (2008) Donepezil treatment of patients with severe Alzheimer\u2019s disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial. Dement Geriatr Cogn Disord 25(5):399\u2013407","journal-title":"Dement Geriatr Cogn Disord"},{"key":"2999_CR28","unstructured":"IQWiG (2008) Ginkgohaltige Pr\u00e4parate bei Alzheimer Demenz. Abschlussbericht A05\u201319B. Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), K\u00f6ln"},{"key":"2999_CR29","unstructured":"IQWiG (2009) Memantin bei Alzheimer Demenz Abschlussbericht A05\u201319D. Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), K\u00f6ln, S 59"},{"key":"2999_CR30","first-page":"CD002854","volume":"Rev","author":"Isaac","year":"2008","unstructured":"Isaac MG, Quinn R, Tabet N (2008) Vitamin E for Alzheimer\u2019s disease and mild cognitive impairment. Cochrane Database Syst Rev (3):CD002854","journal-title":"Cochrane Database Syst"},{"key":"2999_CR31","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/bmj.331.7512.321","volume":"331","author":"Kaduszkiewicz","year":"2005","unstructured":"Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, Bussche H van den (2005) Cholinesterase inhibitors for patients with Alzheimer\u2019s disease: systematic review of randomised clinical trials. BMJ 331(7512):321\u2013327","journal-title":"BMJ"},{"key":"2999_CR32","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S1474-4422(07)70195-3","volume":"6","author":"Kavirajan","year":"2007","unstructured":"Kavirajan H, Schneider LS (2007) Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol 6(9):782\u2013792","journal-title":"Lancet Neurol"},{"key":"2999_CR33","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000113034","volume":"25","author":"Kertesz","year":"2008","unstructured":"Kertesz A, Morlog D, Light M et al (2008) Galantamine in frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cogn Disord 25(2):178\u2013185","journal-title":"Dement Geriatr Cogn Disord"},{"key":"2999_CR34","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1159\/000077171","volume":"17","author":"Lebert","year":"2004","unstructured":"Lebert F, Stekke W, Hasenbroekx C, Pasquier F (2004) Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord 17(4):355\u2013359","journal-title":"Dement Geriatr Cogn Disord"},{"key":"2999_CR35","first-page":"CD000147","volume":"Rev","author":"Lopez-Arrieta","year":"2002","unstructured":"Lopez-Arrieta JM, Birks J (2002) Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev (3):CD000147","journal-title":"Cochrane Database Syst"},{"key":"2999_CR36","first-page":"CD004747","volume":"Rev","author":"Maidment","year":"2006","unstructured":"Maidment I, Fox C, Boustani M (2006) Cholinesterase inhibitors for Parkinson\u2019s disease dementia. Cochrane Database Syst Rev (1):CD004747","journal-title":"Cochrane Database Syst"},{"key":"2999_CR37","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/archneur.65.12.noc80051","volume":"65","author":"Martin","year":"2008","unstructured":"Martin BK, Szekely C, Brandt J et al (2008) Cognitive function over time in the Alzheimer\u2019s Disease Antiinflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 65(7):896\u2013905","journal-title":"Arch Neurol"},{"key":"2999_CR38","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(00)03399-7","volume":"356","author":"McKeith","year":"2000","unstructured":"McKeith I, Del Ser T, Spano P et al (2000) Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study. Lancet 356(9247):2031\u20132036","journal-title":"Lancet"},{"key":"2999_CR39","first-page":"CD003154","volume":"Rev","author":"McShane","year":"2006","unstructured":"McShane R, Areosa Sastre A, Minakaran N (2006) Memantine for dementia. Cochrane Database Syst Rev (2):CD003154","journal-title":"Cochrane Database Syst"},{"key":"2999_CR40","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1532-5415.1989.tb05688.x","volume":"37","author":"Meyer","year":"1989","unstructured":"Meyer JS, Rogers RL, McClintic K et al (1989) Randomized clinical trial of daily aspirin therapy in multi-infarct dementia. A pilot study. J Am Geriatr Soc 37(6):549\u2013555","journal-title":"J Am Geriatr Soc"},{"key":"2999_CR41","first-page":"CD000359","volume":"Rev","author":"Olin","year":"2001","unstructured":"Olin J, Schneider L, Novit A, Luczak S (2001) Hydergine for dementia. Cochrane Database Syst Rev (2):CD000359","journal-title":"Cochrane Database Syst"},{"key":"2999_CR42","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1161\/01.STR.0000155686.73908.3e","volume":"36","author":"Pantoni","year":"2005","unstructured":"Pantoni L, del Ser T, Soglian AG et al (2005) Efficacy and safety of nimodipine in subcortical vascular dementia: a randomized placebo-controlled trial. Stroke 36(3):619\u2013624","journal-title":"Stroke"},{"key":"2999_CR43","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/j.1742-1241.2008.01869.x","volume":"62","author":"Poewe","year":"2008","unstructured":"Poewe W, Gauthier S, Aarsland D et al (2008) Diagnosis and management of Parkinson\u2019s disease dementia. Int J Clin Pract 62(10):1581\u20131587","journal-title":"Int J Clin Pract"},{"key":"2999_CR44","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2174\/156720508783884576","volume":"5","author":"Porsteinsson","year":"2008","unstructured":"Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT (2008) Memantine treatment in patients with mild to moderate Alzheimer\u2019s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebocontrolled trial. Curr Alzheimer Res 5(1):83\u201389","journal-title":"Curr Alzheimer Res"},{"key":"2999_CR45","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1212\/WNL.62.1.66","volume":"62","author":"Reines","year":"2004","unstructured":"Reines SA, Block GA, Morris JC et al (2004) Rofecoxib: no effect on Alzheimer\u2019s disease in a 1-year, randomized, blinded, controlled study. Neurology 62(1):66\u201371","journal-title":"Neurology"},{"key":"2999_CR46","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/BF02246209","volume":"117","author":"Saletu","year":"1995","unstructured":"Saletu B, Paulus E, Linzmayer L et al (1995) Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia: a double-blind, placebo-controlled, clinical and EEG\/ERP mapping study. Psychopharmacology 117(4):385\u2013395","journal-title":"Psychopharmacology"},{"key":"2999_CR47","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1212\/WNL.53.1.197","volume":"53","author":"Scharf","year":"1999","unstructured":"Scharf S, Mander A, Ugoni A et al (1999) A double-blind, placebo-controlled trial of diclofenac\/misoprostol in Alzheimer\u2019s disease. Neurology 53(1):197\u2013201","journal-title":"Neurology"},{"key":"2999_CR48","unstructured":"Schwabe U, Paffrath D (eds) (2008) Arzneiverordnungsreport 2008: Aktuelle Daten, Kosten, Trends und Kommentare. 1. Aufl. Springer, Berlin"},{"key":"2999_CR49","first-page":"CD004031","volume":"Rev","author":"Tabet","year":"2003","unstructured":"Tabet N, Feldman H (2003) Ibuprofen for Alzheimer\u2019s disease. Cochrane Database Syst Rev (2):CD004031","journal-title":"Cochrane Database Syst"},{"key":"2999_CR50","first-page":"CD003673","volume":"Rev","author":"Tabet","year":"2002","unstructured":"Tabet N, Feldman H (2002) Indomethacin for the treatment of Alzheimer\u2019s disease patients. Cochrane Database Syst Rev (2):CD003673","journal-title":"Cochrane Database Syst"},{"key":"2999_CR51","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/jama.291.3.317","volume":"291","author":"Tariot","year":"2004","unstructured":"Tariot PN, Farlow MR, Grossberg GT et al (2004) Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. Jama 291(3):317\u2013324","journal-title":"Jama"},{"key":"2999_CR52","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00702-007-0630-y","volume":"114","author":"Wei","year":"2007","unstructured":"Wei ZH, He QB, Wang H et al (2007) Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer\u2019s disease. J Neural Transm 114(5):629\u2013634","journal-title":"J Neural Transm"},{"key":"2999_CR53","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1055\/s-2000-7978","volume":"33","author":"Weyer","year":"2000","unstructured":"Weyer G, Eul A, Milde K et al (2000) Cyclandelate in the treatment of patients with mild to moderate primary degenerative dementia of the Alzheimer type or vascular dementia: experience from a placebo controlled multi-center study. Pharmacopsychiatry 33(3):89\u201397","journal-title":"Pharmacopsychiatry"},{"key":"2999_CR54","first-page":"CD003672","volume":"Rev","author":"Wild","year":"2003","unstructured":"Wild R, Pettit T, Burns A (2003) Cholinesterase inhibitors for dementia with Lewy bodies. Cochrane Database Syst Rev (3):CD003672","journal-title":"Cochrane Database Syst"},{"key":"2999_CR55","first-page":"CD001296","volume":"Rev","author":"Williams","year":"2000","unstructured":"Williams PS, Rands G, Orrel M, Spector A (2000) Aspirin for vascular dementia. Cochrane Database Syst Rev (4):CD001296","journal-title":"Cochrane Database Syst"},{"key":"2999_CR56","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1212\/WNL.57.3.489","volume":"57","author":"Winblad","year":"2001","unstructured":"Winblad B, Engedal K, Soininen H et al (2001) A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 57(3):489\u2013495","journal-title":"Neurology"},{"key":"2999_CR57","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1212\/01.wnl.0000281847.17519.e0","volume":"69","author":"Winblad","year":"2007","unstructured":"Winblad B, Grossberg G, Frolich L et al (2007) IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 69(4 Suppl 1):14\u201322","journal-title":"Neurology"},{"key":"2999_CR58","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000102568","volume":"24","author":"Winblad","year":"2007","unstructured":"Winblad B, Jones RW, Wirth Y et al (2007) Memantine in moderate to severe Alzheimer\u2019s disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord 24(1):20\u201327","journal-title":"Dement Geriatr Cogn Disord"},{"key":"2999_CR59","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0140-6736(06)68350-5","volume":"367","author":"Winblad","year":"2006","unstructured":"Winblad B, Kilander L, Eriksson S et al (2006) Donepezil in patients with severe Alzheimer\u2019s disease: double-blind, parallel-group, placebo-controlled study. Lancet 367(9516):1057\u20131065","journal-title":"Lancet"},{"key":"2999_CR60","doi-asserted-by":"crossref","unstructured":"Winblad B, Wimo A, Engedal K et al (2006) 3-year study of donepezil therapy in Alzheimer\u2019s disease: effects of early and continuous therapy. Dement Geriatr Cogn Disord 21(5\u20136):353\u2013363","DOI":"10.1159\/000091790"},{"key":"2999_CR61","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S1474-4422(09)70146-2","volume":"8","author":"Aarsland","year":"2009","unstructured":"Aarsland D, Ballard C, Walker Z et al (2009) Memantine in patients with Parkinson\u2019s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 8(7):613\u2013618","journal-title":"Lancet Neurol"},{"key":"2999_CR62","unstructured":"IQWiG (2007) Cholinesterasehemmer bei Alzheimer-Demenz. Abschlussbericht A05-19A. K\u00f6ln: Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); K\u00f6ln S"},{"key":"2999_CR63","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00002093-200301000-00006","volume":"17","author":"Sha","year":"2003","unstructured":"Sha MC, Callahan CM (2003) The efficacy of pentoxifylline in the treatment of vascular dementia: a systematic review. Alzheimer Dis Assoc Disord 17(1):46\u201354","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"2999_CR64","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1600-0404.1996.tb00026.x","volume":"93","author":"Parnetti","year":"1996","unstructured":"Parnetti L, Ambrosoli L, Agliati G et al (1996) osatirelin in the treatment of vascular dementia: a double-blind multicentre study vs placebo. Acta Neurol Scand 93(6):456\u2013463","journal-title":"Acta Neurol Scand"},{"key":"2999_CR65","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000119288","volume":"34","author":"Fischhof","year":"1996","unstructured":"Fischhof PK, Moslinger-Gehmayr R, Herrmann WM et al (1996) Therapeutic efficacy of vincamine in dementia. Neuropsychobiology 34(1):29\u201335","journal-title":"Neuropsychobiology"},{"key":"2999_CR66","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/PL00007541","volume":"251","author":"M\u00f6ller","year":"2001","unstructured":"M\u00f6ller HJ, Hartmann A, Kessler C et al (2001) Naftidrofuryl in the treatment of vascular dementia. Eur Arch Psychiatry Clin Neurosci 251(6):247\u2013254","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"2999_CR67","doi-asserted-by":"crossref","unstructured":"Frampton M, Harvey RJ, Kirchner V (2003) Propentofylline for dementia. Cochrane Database Syst Rev CD002853","DOI":"10.1002\/14651858.CD002853"},{"key":"2999_CR68","doi-asserted-by":"crossref","unstructured":"Szatmari SZ, Whitehouse PJ (2003) Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst Rev CD003119","DOI":"10.1002\/14651858.CD003119"},{"key":"2999_CR69","doi-asserted-by":"crossref","unstructured":"Treves TA, Korczyn A. (1999) Denbufylline in dementia: a double-blind controlled study. Dement Geriatr Cogn Disord. 10(6):505\u2013510","DOI":"10.1159\/000017197"},{"key":"2999_CR70","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0167-4943(92)90059-D","volume":"15","author":"Marigliano","year":"1992","unstructured":"Marigliano V, Abate G, Barbagallo-Sangiorgi G et al (1992) Randomized, double-blind, placebo controlled, multicentre study of idebenone in patients suffering from multi-infarct dementia. Arch Gerontol Geriatr 15(3):239\u2013248","journal-title":"Arch Gerontol Geriatr"},{"key":"2999_CR71","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1177\/030006059202000206","volume":"20","author":"Cucinotta","year":"1992","unstructured":"Cucinotta D, Aveni Casucci MA, Pedrazzi F et al (1992) Multicentre clinical placebo-controlled study with buflomedil in the treatment of mild dementia of vascular origin. J Int Med Res 20(2):136\u2013149","journal-title":"J Int Med Res"},{"key":"2999_CR72","doi-asserted-by":"crossref","unstructured":"Fischhof PK, Saletu B, Ruther E et al (1992) Therapeutic efficacy of pyritinol in patients with senile dementia of the Alzheimer type (SDAT) and multi-infarct dementia (MID). Neuropsychobiology 26(1-2):65\u201370","DOI":"10.1159\/000118898"},{"key":"2999_CR73","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1185\/03007998909110460","volume":"11","author":"Arrigo","year":"1989","unstructured":"Arrigo A, Casale R, Giorgi I et al (1989) Effects of intravenous high dose co-dergocrine mesylate (\u201aHydergine\u2018) in elderly patients with severe multi-infarct dementia: a double-blind, placebo-controlled trial. Curr Med Res Opin 11(8):491\u2013500","journal-title":"Curr Med Res Opin"},{"key":"2999_CR74","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0049-3848(97)00122-9","volume":"87","author":"Parnetti","year":"1997","unstructured":"Parnetti L, Mari D, Abate G et al (1997) Vascular dementia Italian sulodexide study (VA.D.I.S.S.). Clinical and biological results. Thromb Res 87(2):225\u2013233","journal-title":"Thromb Res"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-010-2999-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-010-2999-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-010-2999-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T06:45:45Z","timestamp":1559198745000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-010-2999-3"}},"subtitle":["Symptomatische Therapie der Demenzen"],"short-title":[],"issued":{"date-parts":[[2010,6,25]]},"references-count":74,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["2999"],"URL":"https:\/\/doi.org\/10.1007\/s00115-010-2999-3","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,25]]}}}